| Outcome Measures: |
Primary: Rate of Inducing Diabetes Remission, At the end of 12-week treatment|Change of Rate of Maintaining Diabetes Remission, 3,6,12,24,36 months after 12-week treatment|Time of Maintaining Diabetes Remission, up to 36 months after 12-week treatment | Secondary: Change of Blood Pressure, Baseline and 0,3,6,12,24,36 months after 12-week treatment|Change of Heart Rate, baseline and 0,3,6,12,24,36 months after 12-week treatment|Change of Weight, baseline and 0,3,6,12,24,36 months after 12-week treatment|Change of Waistline, baseline and 0,3,6,12,24,36 months after 12-week treatment|Change of Glycosylated Hemoglobin, baseline and 0,3,6,12,24,36 months after 12-week treatment|Change of Pancreatic Beta-cell Function, Pancreatic Beta-cell Function will be evaluated by insulin releasing test. The fasting and 2-hour postprandial plasma glucose concentrations and serum insulin concentrations will be tested., baseline and 0,3,6,12,24,36 months after 12-week treatment|Change of Insulin Resistance Index, baseline and 0,3,6,12,24,36 months after 12-week treatment|The Incidence of Hypoglycemia, During the 12-week treatment|The Incidence of Diabetic Retinopathy, up to 36 months after 12-week treatment|The Incidence of Diabetic Nephropathy, up to 36 months after 12-week treatment
|
